Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management : Episode 7
Incorporating ctDNA-Based MRD Testing and Study Findings Into Clinical Practice
Medical experts examine how recent data on circulating tumor DNA-based minimal residual disease testing may impact the clinical management and treatment of colorectal cancer.
- Please discuss the clinical implications of these recent data for the utility of ctDNA-based MRD testing in CRC treatment and management
- Are any of these findings practice-changing?
- Are you routinely testing patients after surgery and after adjuvant therapy on the basis of these data?
- What are some barriers to enrollment surrounding MRD testing in CRC for ongoing adjuvant studies (like CIRCULATE)?
- Are patients wanting to escalate or de-escalate treatment?
- How are patients reacting to study testing?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
